FibroScan (VCTE): What This Liver Test Actually Measures

What FibroScan and VCTE Actually Mean

FibroScan is the commercial name for a device manufactured by Echosens that performs vibration-controlled transient elastography. The test sends a low-frequency shear wave (50 Hz) through the liver via a probe placed on the skin between the ribs on the right side of the body. The device then measures how fast that wave travels through hepatic tissue.

Stiffer tissue transmits the wave faster. The device converts wave velocity into a stiffness value expressed in kilopascals (kPa). A second measurement, the controlled attenuation parameter (CAP), captures ultrasound attenuation as the wave passes through liver tissue. Fat droplets within hepatocytes scatter and absorb ultrasound energy, so higher CAP values indicate more fat [1].

The exam requires no sedation, no needles, and no radiation. Patients lie on their back with the right arm raised behind the head. A trained operator places the probe in the right intercostal space and takes 10 valid acquisitions. The device reports a median stiffness value and interquartile range (IQR). A valid exam requires 10 successful shots, a success rate of at least 60%, and an IQR-to-median ratio below 30% [2]. The entire process takes roughly 10 minutes. A 2013 meta-analysis in Gastroenterology (N=5,124 across 50 studies) confirmed that VCTE has an area under the receiver operating characteristic curve (AUROC) of 0.84 for detecting significant fibrosis (F≥2) and 0.94 for detecting cirrhosis (F4) [3].

The Two Numbers: Liver Stiffness and CAP Score

Every FibroScan report produces two distinct values, and confusing them is a common mistake. Understanding what each number represents is the first step toward interpreting results correctly.

Liver stiffness (kPa) reflects the degree of fibrosis, or scarring, in the liver. Healthy liver tissue is soft and elastic. As chronic inflammation deposits collagen fibers between hepatocytes, tissue becomes rigid. The EASL-ALEH clinical practice guidelines define the following stiffness thresholds for chronic liver disease of various etiologies [4]:

• F0 to F1 (no to mild fibrosis): below 7.0 kPa
• F2 (significant fibrosis): 7.0 to 9.5 kPa
• F3 (advanced fibrosis): 9.5 to 12.5 kPa
• F4 (cirrhosis): above 12.5 kPa

These cutoffs shift slightly depending on the underlying disease. In chronic hepatitis B, the AASLD recommends a lower threshold of 6.0 kPa for ruling out significant fibrosis [5]. In metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), the AACE 2023 consensus statement uses 8.0 kPa as the threshold separating low-risk from intermediate-risk patients [6].

CAP score (dB/m) estimates steatosis grade. A 2017 meta-analysis of 2,735 patients found the following optimal cutoffs: S0 (no steatosis) below 238 dB/m, S1 (mild, 5 to 33% fat) 238 to 260 dB/m, S2 (moderate, 34 to 66% fat) 260 to 290 dB/m, and S3 (severe, above 66% fat) above 290 dB/m [7]. CAP has moderate diagnostic accuracy (AUROC 0.82 for S≥1) but shows ceiling effects at very high fat fractions, where values cluster between 350 and 400 dB/m regardless of actual fat percentage.

Why Clinicians Order FibroScan for MASLD Staging

MASLD affects an estimated 30% of adults worldwide according to a 2023 meta-analysis published in Hepatology (N=12.5 million across 72 countries) [8]. Identifying which of those patients have progressed to significant fibrosis is the central clinical question, because fibrosis stage is the strongest predictor of liver-related mortality.

Liver biopsy remains the histological reference standard, but it samples only 1/50,000th of the organ, carries a 0.01 to 0.1% risk of serious hemorrhage, and causes enough pain to require monitoring for several hours [9]. The American Gastroenterological Association's 2023 clinical practice guideline on MASLD screening recommends non-invasive tests, including VCTE, as the preferred first-line approach for risk stratification in primary care [10].

The AGA guideline suggests a two-step pathway: first, calculate the Fibrosis-4 (FIB-4) index from routine blood work (age, AST, ALT, platelet count). If FIB-4 falls between 1.3 and 2.67 (the indeterminate zone), proceed to VCTE. A stiffness result below 8.0 kPa rules out advanced fibrosis with a negative predictive value exceeding 90%, while a result above 12.0 kPa rules it in with high specificity [10].

Dr. Rohit Loomba, director of the MASLD Research Center at UC San Diego, has stated: "VCTE is the most validated non-invasive tool we have for fibrosis staging in fatty liver disease. It does not replace biopsy for every clinical question, but it has replaced biopsy as the gatekeeper for identifying who needs subspecialty referral" [11].

FibroScan and Resmetirom (Rezdiffra) Eligibility

The FDA approved resmetirom (Rezdiffra) in March 2024 for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced fibrosis (F2 or F3). This made resmetirom the first drug ever approved specifically for MASH [12].

Identifying F2 or F3 fibrosis is a prerequisite for prescribing the drug. The MAESTRO-NASH trial (N=966) used liver biopsy for enrollment, but the AACE and AGA have both acknowledged that VCTE-based fibrosis assessment is acceptable for clinical decision-making outside a trial setting when biopsy is not feasible [6][10].

In the MAESTRO-NASH trial, resmetirom 100 mg daily achieved MASH resolution without worsening fibrosis in 29.9% of patients at 52 weeks, compared to 9.7% for placebo. The 80 mg dose achieved fibrosis improvement by at least one stage (without worsening of NASH Activity Score) in 25.9% vs. 14.2% for placebo [13]. These endpoints were confirmed by paired liver biopsies, but ongoing post-marketing monitoring may rely heavily on FibroScan to track stiffness changes over time.

A stiffness reading between 8.0 and 12.5 kPa in a patient with established MASLD and metabolic risk factors (type 2 diabetes, obesity, elevated ALT) places that individual squarely in the population that may benefit from resmetirom evaluation.

What Affects Your Results (and What Invalidates Them)

FibroScan is reproducible, but several factors inflate liver stiffness readings independent of fibrosis. Recognizing these confounders prevents misinterpretation.

Eating before the exam raises stiffness. A 2015 study in the Journal of Hepatology showed that postprandial measurements increased liver stiffness by a mean of 1.5 kPa compared to fasting values, enough to push a borderline F1 patient into the F2 range [14]. Standard protocol requires a 2 to 3 hour fast.

Acute hepatitis flares with ALT above 5 times the upper limit of normal can double measured stiffness due to inflammation and edema, not fibrosis [15]. Clinicians should defer testing until transaminases stabilize.

Congestive heart failure and hepatic congestion increase right-sided venous pressure, distending hepatic sinusoids and raising stiffness. A patient with decompensated heart failure may register stiffness values in the cirrhosis range despite having no collagen deposition whatsoever [16].

Obesity affects probe selection. The standard M probe is validated for a skin-to-liver-capsule distance below 25 mm. When subcutaneous adipose tissue exceeds this distance (common at BMI above 30), the XL probe must be used. A 2012 Hepatology study demonstrated that the XL probe reduced failure rates from 16% to 1.1% in obese patients while maintaining diagnostic accuracy [17].

Ascites blocks shear wave transmission entirely. Free fluid absorbs the wave before it reaches hepatic parenchyma, producing unreliable or failed readings. VCTE cannot be performed in patients with moderate or large-volume ascites [2].

How to Interpret Your FibroScan Score: A Practical Breakdown

Receiving a FibroScan report can be confusing without context. Below is a framework for understanding what different stiffness and CAP combinations mean in practice for patients with suspected or confirmed MASLD.

Low stiffness (below 7.0 kPa) with low CAP (below 238 dB/m): No evidence of significant liver fat or fibrosis. If metabolic risk factors are present, repeat screening with FIB-4 annually and VCTE every 2 to 3 years per AGA recommendations [10].

Low stiffness (below 7.0 kPa) with elevated CAP (above 260 dB/m): Steatosis is present without significant scarring. This is the window for aggressive lifestyle intervention. A 2019 study in the Journal of Hepatology showed that 7 to 10% total body weight loss reduced liver fat by a mean of 65% and resolved steatohepatitis in 59% of participants [18].

Intermediate stiffness (7.0 to 9.5 kPa) with elevated CAP: This is the range that triggers the most clinical uncertainty. Repeat testing in 6 to 12 months is standard. If the value persists or rises, referral to hepatology is appropriate.

High stiffness (above 9.5 kPa) with any CAP: Advanced fibrosis or cirrhosis is likely. The BAVENO VII consensus recommends that patients with VCTE above 20 to 25 kPa and a platelet count above 150,000/µL can safely avoid screening endoscopy for varices, while those with higher stiffness or lower platelets should be scoped [19].

The Endocrine Society's 2024 clinical practice guideline on MASLD notes that trending stiffness values over time may be more informative than a single measurement, particularly when monitoring response to weight loss or pharmacotherapy [20].

How to Lower Your FibroScan Score

Reducing liver stiffness requires addressing the root cause of hepatic injury. In MASLD, the evidence-based strategies are weight loss, glucose optimization, and (when indicated) pharmacotherapy.

Weight loss remains the most effective intervention. The Cuban NAFLD trial and a landmark 2015 Gastroenterology study (N=293) demonstrated that at least 10% total body weight loss resulted in fibrosis regression in 45% of participants, compared to 21% in those losing less than 5% [21]. GLP-1 receptor agonists contribute both through weight reduction and potential direct hepatic effects. In the LEAN trial (N=52), liraglutide 1.8 mg daily resolved NASH in 39% of participants versus 9% with placebo over 48 weeks [22]. Semaglutide 2.4 mg showed even larger effects on steatohepatitis resolution in the phase 2 trial published in the New England Journal of Medicine, with 59% resolution at the highest dose versus 17% placebo [23].

Pioglitazone 30 to 45 mg daily has level A evidence from the PIVENS trial (N=247) for NASH resolution in patients with or without type 2 diabetes [24]. The AACE 2023 consensus algorithm lists pioglitazone and GLP-1 RAs as first-line pharmacologic options when lifestyle modification alone is insufficient [6].

Dr. Mary Rinella, who chaired the multi-society Delphi consensus that renamed NAFLD to MASLD, has noted: "The shift from NAFLD to MASLD is not just semantic. It refocuses the field on metabolic drivers and removes the stigmatizing 'fatty' label, which we know reduced patient engagement with screening" [25].

Alcohol cessation is relevant for patients with any degree of alcohol use. Even moderate intake (7 to 14 drinks per week) accelerates fibrosis progression in patients who already have hepatic steatosis from metabolic causes [26].

How FibroScan Compares to Other Non-Invasive Tests

VCTE is not the only non-invasive fibrosis assessment tool. Understanding where it fits relative to alternatives helps patients and clinicians choose appropriately.

FIB-4 index is free, calculated from routine labs, and serves as an excellent screening tool. Its weakness is a wide indeterminate zone (1.3 to 2.67) that captures roughly 30 to 40% of screened patients, all of whom need a second test [10].

Magnetic resonance elastography (MRE) measures liver stiffness using MRI-based shear wave imaging. MRE has higher accuracy than VCTE for detecting intermediate fibrosis stages (F2 and F3), with an AUROC of 0.92 versus 0.84 for VCTE at F≥2 [27]. The trade-off: MRE costs $800 to $2,000 per exam, requires 30 to 45 minutes of scanner time, and is unavailable in many community settings. VCTE costs $150 to $350 and can be performed in a primary care office.

MRI-PDFF (proton density fat fraction) is the gold standard for quantifying hepatic fat, outperforming CAP at every steatosis grade. If the primary clinical question is "how much fat is in the liver," MRI-PDFF wins. If the question is "does this patient have significant fibrosis," VCTE is faster, cheaper, and nearly as accurate.

Enhanced Liver Fibrosis (ELF) test is a blood-based panel of three direct fibrosis biomarkers (hyaluronic acid, TIMP-1, PIIINP). The NICE guidelines in the United Kingdom recommend ELF as the second-line test after FIB-4, but ELF is not widely available in the United States and is not FDA-cleared for MASLD-specific use [28].

What a High FibroScan Score Means for Long-Term Health

A liver stiffness value above 12.5 kPa, consistent with cirrhosis, carries implications beyond the liver. Patients with compensated cirrhosis from MASLD have a 10-year liver-related mortality rate of approximately 10%, which rises sharply once decompensation events (ascites, variceal bleeding, hepatic encephalopathy) occur [29].

A 2021 study in Gut followed 3,271 patients with VCTE-assessed liver stiffness and found that every 1 kPa increase above 8.0 kPa was associated with a 5% relative increase in cardiovascular mortality, independent of traditional risk factors [30]. This finding reinforces the concept that liver fibrosis is a systemic metabolic signal, not an isolated organ problem.

Surveillance for hepatocellular carcinoma (HCC) is recommended in all patients with cirrhosis regardless of etiology. The AASLD recommends ultrasound with or without alpha-fetoprotein every 6 months [5]. A FibroScan value above 20 kPa identifies patients at the highest HCC risk and should prompt immediate enrollment in a surveillance program.